INMUNE BIO, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.76 USD | +3.18% |
|
+0.46% | -22.20% |
| May. 30 | Sector Update: Health Care Stocks Higher in Afternoon Trading | MT |
| May. 30 | INmune Bio to Join Russell 3000 Index in July | MT |
Presentation Operator MessageOperator (Operator)Greetings and welcome to the INmune Bio Third ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.
Calendar
2024-07-18
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.49
USD
Average target price
19.67
USD
Spread / Average Target
+131.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.20% | 168M | |
| +16.72% | 124B | |
| +17.59% | 112B | |
| +3.96% | 22.94B | |
| -10.60% | 17.02B | |
| -16.66% | 16.88B | |
| -39.94% | 16.87B | |
| +2.46% | 13.63B | |
| +26.52% | 11.61B | |
| +101.42% | 10.31B |
- Stock Market
- Equities
- INMB Stock
- News INmune Bio, Inc.
- Transcript : INmune Bio, Inc., Q3 2020 Earnings Call, Nov 05, 2020
